Loading…
The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
The present study investigated the clinical implications of pretreatment carbohydrate antigen 125 (CA-125) levels and CA-125 normalization in patients with ovarian clear cell carcinoma (CCC), and it provides useful information for the improvement of monitoring strategies for this lethal disease. The...
Saved in:
| Published in: | Oncotarget 2016-03, Vol.7 (13), p.15566-15576 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c354t-94df42def93bb33737ee69a9537062636379b46ab9d7c3bb5c483d669d9a4fe53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c354t-94df42def93bb33737ee69a9537062636379b46ab9d7c3bb5c483d669d9a4fe53 |
| container_end_page | 15576 |
| container_issue | 13 |
| container_start_page | 15566 |
| container_title | Oncotarget |
| container_volume | 7 |
| creator | Bai, Huimin Sha, Guisha Xiao, Meizhu Gao, Huiqiao Cao, Dongyan Yang, Jiaxin Chen, Jie Wang, Yue Zhang, Zhenyu Shen, Keng |
| description | The present study investigated the clinical implications of pretreatment carbohydrate antigen 125 (CA-125) levels and CA-125 normalization in patients with ovarian clear cell carcinoma (CCC), and it provides useful information for the improvement of monitoring strategies for this lethal disease.
The medical records of patients with ovarian CCC who had undergone primary staging surgery or cytoreductive surgery followed by systemic chemotherapy were retrospectively reviewed. A range of clinico-pathological parameters were collected and examined.
A total of 375 women were included in the analysis. FIGO stage (p < 0.001) was identified as the only significant prognostic factor for relapse. Residual tumor and advanced stage (p = 0.001 and p < 0.001, respectively) were identified as independent adverse factors for survival. The potential risk factors associated with elevated pretreatment CA-125 levels included advanced-stage disease, positive residual tumors and negative endometriosis (p < 0.001, p = 0.001 and p |
| doi_str_mv | 10.18632/oncotarget.7216 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4941261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1791325744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-94df42def93bb33737ee69a9537062636379b46ab9d7c3bb5c483d669d9a4fe53</originalsourceid><addsrcrecordid>eNpVUU1vFDEMjSpQW5Xee0I5cpky-ZjMhgNStaKAVIlLe448iWcblEmWJLOo_Qv86c7SD4ovtuznZz89Qs5Ye85WSvCPKdpUIW-wnvecqQNyzLTUDe868eZVfUROS_nZLtHJfsX1ITniaiFQQh-TP9e3SLc5bWIq1Vu6gzAjTePSw5oR6oSx0vVFw3hHA-4wFArRPXdiyhMEfw_Vp0h9pGkH2UOkNiBkajEEaiFbH9MEnyjQ-js1YMHh5G3j43KzzhVpqbO7e0fejhAKnj7lE3Jz-eV6_a25-vH1-_riqrGik7XR0o2SOxy1GAYhetEjKg26E32r-F5XrwepYNCutwuks3IlnFLaaZAjduKEfH7k3c7DhM4uCjMEs81-gnxnEnjz_yT6W7NJOyO1ZFyxheDDE0FOv2Ys1Uy-7LVCxDQXw3rNBO96KRdo-wi1OZWScXw5w1rz10bzz0azt3FZef_6vZeFZ9PEA1nineg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1791325744</pqid></control><display><type>article</type><title>The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study</title><source>PubMed Central</source><creator>Bai, Huimin ; Sha, Guisha ; Xiao, Meizhu ; Gao, Huiqiao ; Cao, Dongyan ; Yang, Jiaxin ; Chen, Jie ; Wang, Yue ; Zhang, Zhenyu ; Shen, Keng</creator><creatorcontrib>Bai, Huimin ; Sha, Guisha ; Xiao, Meizhu ; Gao, Huiqiao ; Cao, Dongyan ; Yang, Jiaxin ; Chen, Jie ; Wang, Yue ; Zhang, Zhenyu ; Shen, Keng</creatorcontrib><description>The present study investigated the clinical implications of pretreatment carbohydrate antigen 125 (CA-125) levels and CA-125 normalization in patients with ovarian clear cell carcinoma (CCC), and it provides useful information for the improvement of monitoring strategies for this lethal disease.
The medical records of patients with ovarian CCC who had undergone primary staging surgery or cytoreductive surgery followed by systemic chemotherapy were retrospectively reviewed. A range of clinico-pathological parameters were collected and examined.
A total of 375 women were included in the analysis. FIGO stage (p < 0.001) was identified as the only significant prognostic factor for relapse. Residual tumor and advanced stage (p = 0.001 and p < 0.001, respectively) were identified as independent adverse factors for survival. The potential risk factors associated with elevated pretreatment CA-125 levels included advanced-stage disease, positive residual tumors and negative endometriosis (p < 0.001, p = 0.001 and p <0.001, respectively). Pretreatment CA-125 levels were not associated with relapse-free survival (RFS) or overall survival (OS) (p = 0.060 and p = 0.176, respectively). CA-125 normalization after chemotherapy exhibited a positive linear correlation with advanced stage (r = 0.97, p = 0.001) and residual tumor (r = 0.81, p = 0.027) and a negative relationship with 5-year RFS (r = -0.97, p = 0.002) and 5-year OS (r = -0.97, p= 0.001). Patients with CA-125 levels that normalized before cycle 2 of chemotherapy had a similar prognosis as patients whose CA-125 levels normalized prior to chemotherapy (RFS: p = 0.327; OS: p = 0.654). By contrast, patients with CA-125 levels that normalized after cycle 2 of chemotherapy or never normalized were significantly more likely to experience disease progression.
Pretreatment CA-125 levels are not very useful for predicting clinical outcome. CA-125 levels following treatment are a valid indicator for treatment monitoring. CA-125 normalization after the completion of cycle 1 of chemotherapy represents a distinct inflection point for decreased RFS and OS.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.7216</identifier><identifier>PMID: 26863639</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Adenocarcinoma, Clear Cell - blood ; Adenocarcinoma, Clear Cell - drug therapy ; Adenocarcinoma, Clear Cell - mortality ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - blood ; CA-125 Antigen - blood ; Carcinoma, Ovarian Epithelial ; Female ; Humans ; Middle Aged ; Neoplasms, Glandular and Epithelial - blood ; Neoplasms, Glandular and Epithelial - drug therapy ; Neoplasms, Glandular and Epithelial - mortality ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - mortality ; Prognosis ; Research Paper</subject><ispartof>Oncotarget, 2016-03, Vol.7 (13), p.15566-15576</ispartof><rights>Copyright: © 2016 Bai et al. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-94df42def93bb33737ee69a9537062636379b46ab9d7c3bb5c483d669d9a4fe53</citedby><cites>FETCH-LOGICAL-c354t-94df42def93bb33737ee69a9537062636379b46ab9d7c3bb5c483d669d9a4fe53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941261/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941261/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26863639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Huimin</creatorcontrib><creatorcontrib>Sha, Guisha</creatorcontrib><creatorcontrib>Xiao, Meizhu</creatorcontrib><creatorcontrib>Gao, Huiqiao</creatorcontrib><creatorcontrib>Cao, Dongyan</creatorcontrib><creatorcontrib>Yang, Jiaxin</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><creatorcontrib>Zhang, Zhenyu</creatorcontrib><creatorcontrib>Shen, Keng</creatorcontrib><title>The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>The present study investigated the clinical implications of pretreatment carbohydrate antigen 125 (CA-125) levels and CA-125 normalization in patients with ovarian clear cell carcinoma (CCC), and it provides useful information for the improvement of monitoring strategies for this lethal disease.
The medical records of patients with ovarian CCC who had undergone primary staging surgery or cytoreductive surgery followed by systemic chemotherapy were retrospectively reviewed. A range of clinico-pathological parameters were collected and examined.
A total of 375 women were included in the analysis. FIGO stage (p < 0.001) was identified as the only significant prognostic factor for relapse. Residual tumor and advanced stage (p = 0.001 and p < 0.001, respectively) were identified as independent adverse factors for survival. The potential risk factors associated with elevated pretreatment CA-125 levels included advanced-stage disease, positive residual tumors and negative endometriosis (p < 0.001, p = 0.001 and p <0.001, respectively). Pretreatment CA-125 levels were not associated with relapse-free survival (RFS) or overall survival (OS) (p = 0.060 and p = 0.176, respectively). CA-125 normalization after chemotherapy exhibited a positive linear correlation with advanced stage (r = 0.97, p = 0.001) and residual tumor (r = 0.81, p = 0.027) and a negative relationship with 5-year RFS (r = -0.97, p = 0.002) and 5-year OS (r = -0.97, p= 0.001). Patients with CA-125 levels that normalized before cycle 2 of chemotherapy had a similar prognosis as patients whose CA-125 levels normalized prior to chemotherapy (RFS: p = 0.327; OS: p = 0.654). By contrast, patients with CA-125 levels that normalized after cycle 2 of chemotherapy or never normalized were significantly more likely to experience disease progression.
Pretreatment CA-125 levels are not very useful for predicting clinical outcome. CA-125 levels following treatment are a valid indicator for treatment monitoring. CA-125 normalization after the completion of cycle 1 of chemotherapy represents a distinct inflection point for decreased RFS and OS.</description><subject>Adenocarcinoma, Clear Cell - blood</subject><subject>Adenocarcinoma, Clear Cell - drug therapy</subject><subject>Adenocarcinoma, Clear Cell - mortality</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA-125 Antigen - blood</subject><subject>Carcinoma, Ovarian Epithelial</subject><subject>Female</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasms, Glandular and Epithelial - blood</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Neoplasms, Glandular and Epithelial - mortality</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Prognosis</subject><subject>Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVUU1vFDEMjSpQW5Xee0I5cpky-ZjMhgNStaKAVIlLe448iWcblEmWJLOo_Qv86c7SD4ovtuznZz89Qs5Ye85WSvCPKdpUIW-wnvecqQNyzLTUDe868eZVfUROS_nZLtHJfsX1ITniaiFQQh-TP9e3SLc5bWIq1Vu6gzAjTePSw5oR6oSx0vVFw3hHA-4wFArRPXdiyhMEfw_Vp0h9pGkH2UOkNiBkajEEaiFbH9MEnyjQ-js1YMHh5G3j43KzzhVpqbO7e0fejhAKnj7lE3Jz-eV6_a25-vH1-_riqrGik7XR0o2SOxy1GAYhetEjKg26E32r-F5XrwepYNCutwuks3IlnFLaaZAjduKEfH7k3c7DhM4uCjMEs81-gnxnEnjz_yT6W7NJOyO1ZFyxheDDE0FOv2Ys1Uy-7LVCxDQXw3rNBO96KRdo-wi1OZWScXw5w1rz10bzz0azt3FZef_6vZeFZ9PEA1nineg</recordid><startdate>20160329</startdate><enddate>20160329</enddate><creator>Bai, Huimin</creator><creator>Sha, Guisha</creator><creator>Xiao, Meizhu</creator><creator>Gao, Huiqiao</creator><creator>Cao, Dongyan</creator><creator>Yang, Jiaxin</creator><creator>Chen, Jie</creator><creator>Wang, Yue</creator><creator>Zhang, Zhenyu</creator><creator>Shen, Keng</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160329</creationdate><title>The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study</title><author>Bai, Huimin ; Sha, Guisha ; Xiao, Meizhu ; Gao, Huiqiao ; Cao, Dongyan ; Yang, Jiaxin ; Chen, Jie ; Wang, Yue ; Zhang, Zhenyu ; Shen, Keng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-94df42def93bb33737ee69a9537062636379b46ab9d7c3bb5c483d669d9a4fe53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adenocarcinoma, Clear Cell - blood</topic><topic>Adenocarcinoma, Clear Cell - drug therapy</topic><topic>Adenocarcinoma, Clear Cell - mortality</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA-125 Antigen - blood</topic><topic>Carcinoma, Ovarian Epithelial</topic><topic>Female</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasms, Glandular and Epithelial - blood</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Neoplasms, Glandular and Epithelial - mortality</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Prognosis</topic><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Bai, Huimin</creatorcontrib><creatorcontrib>Sha, Guisha</creatorcontrib><creatorcontrib>Xiao, Meizhu</creatorcontrib><creatorcontrib>Gao, Huiqiao</creatorcontrib><creatorcontrib>Cao, Dongyan</creatorcontrib><creatorcontrib>Yang, Jiaxin</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Wang, Yue</creatorcontrib><creatorcontrib>Zhang, Zhenyu</creatorcontrib><creatorcontrib>Shen, Keng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Huimin</au><au>Sha, Guisha</au><au>Xiao, Meizhu</au><au>Gao, Huiqiao</au><au>Cao, Dongyan</au><au>Yang, Jiaxin</au><au>Chen, Jie</au><au>Wang, Yue</au><au>Zhang, Zhenyu</au><au>Shen, Keng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2016-03-29</date><risdate>2016</risdate><volume>7</volume><issue>13</issue><spage>15566</spage><epage>15576</epage><pages>15566-15576</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>The present study investigated the clinical implications of pretreatment carbohydrate antigen 125 (CA-125) levels and CA-125 normalization in patients with ovarian clear cell carcinoma (CCC), and it provides useful information for the improvement of monitoring strategies for this lethal disease.
The medical records of patients with ovarian CCC who had undergone primary staging surgery or cytoreductive surgery followed by systemic chemotherapy were retrospectively reviewed. A range of clinico-pathological parameters were collected and examined.
A total of 375 women were included in the analysis. FIGO stage (p < 0.001) was identified as the only significant prognostic factor for relapse. Residual tumor and advanced stage (p = 0.001 and p < 0.001, respectively) were identified as independent adverse factors for survival. The potential risk factors associated with elevated pretreatment CA-125 levels included advanced-stage disease, positive residual tumors and negative endometriosis (p < 0.001, p = 0.001 and p <0.001, respectively). Pretreatment CA-125 levels were not associated with relapse-free survival (RFS) or overall survival (OS) (p = 0.060 and p = 0.176, respectively). CA-125 normalization after chemotherapy exhibited a positive linear correlation with advanced stage (r = 0.97, p = 0.001) and residual tumor (r = 0.81, p = 0.027) and a negative relationship with 5-year RFS (r = -0.97, p = 0.002) and 5-year OS (r = -0.97, p= 0.001). Patients with CA-125 levels that normalized before cycle 2 of chemotherapy had a similar prognosis as patients whose CA-125 levels normalized prior to chemotherapy (RFS: p = 0.327; OS: p = 0.654). By contrast, patients with CA-125 levels that normalized after cycle 2 of chemotherapy or never normalized were significantly more likely to experience disease progression.
Pretreatment CA-125 levels are not very useful for predicting clinical outcome. CA-125 levels following treatment are a valid indicator for treatment monitoring. CA-125 normalization after the completion of cycle 1 of chemotherapy represents a distinct inflection point for decreased RFS and OS.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>26863639</pmid><doi>10.18632/oncotarget.7216</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2016-03, Vol.7 (13), p.15566-15576 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4941261 |
| source | PubMed Central |
| subjects | Adenocarcinoma, Clear Cell - blood Adenocarcinoma, Clear Cell - drug therapy Adenocarcinoma, Clear Cell - mortality Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - blood CA-125 Antigen - blood Carcinoma, Ovarian Epithelial Female Humans Middle Aged Neoplasms, Glandular and Epithelial - blood Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - mortality Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Prognosis Research Paper |
| title | The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A40%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20prognostic%20value%20of%20pretreatment%20CA-125%20levels%20and%20CA-125%20normalization%20in%20ovarian%20clear%20cell%20carcinoma:%20a%20two-academic-institute%20study&rft.jtitle=Oncotarget&rft.au=Bai,%20Huimin&rft.date=2016-03-29&rft.volume=7&rft.issue=13&rft.spage=15566&rft.epage=15576&rft.pages=15566-15576&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.7216&rft_dat=%3Cproquest_pubme%3E1791325744%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c354t-94df42def93bb33737ee69a9537062636379b46ab9d7c3bb5c483d669d9a4fe53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1791325744&rft_id=info:pmid/26863639&rfr_iscdi=true |